Quince Therapeutics, Inc. — Director's Dealing 2023

Oct 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Quince Therapeutics, Inc. (QNCX)
CIK: 0001662774
Period of Report: 2023-10-23

Reporting Person: Benatti Luca (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-23	Employee Stock Option (right to buy)	$0.99	A	54000	Acquired	2033-10-22	Common Stock (54000)	Direct

Footnotes

F1: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of October 23, 2023, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date.